{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:14:23Z","timestamp":1768641263187,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.vaccine.2018.04.064","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T13:37:56Z","timestamp":1525095476000},"page":"3286-3295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antibody persistence and booster response 68\u202fmonths after vaccination at 2\u201310\u202fyears of age with one dose of MenACWY-TT conjugate vaccine"],"prefix":"10.1016","volume":"36","author":[{"given":"Markus","family":"Knuf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Helm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devayani","family":"Kolhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Van Der Wielen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaela","family":"Baine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.vaccine.2018.04.064_b0005","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine."},{"issue":"suppl 2","key":"10.1016\/j.vaccine.2018.04.064_b0010","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.064_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr."},{"key":"10.1016\/j.vaccine.2018.04.064_b0020","unstructured":"ECDC. Annual epidemiological report reporting on 2011 surveillance data and 2012 epidemic intelligence data <http:\/\/www.ecdc.europa.eu\/en\/publications\/Publications\/Annual-Epidemiological-Report-2013.pdf> [accessed July 2017]."},{"key":"10.1016\/j.vaccine.2018.04.064_b0025","unstructured":"ECDC. Surveillance report. Surveillance of invasive bacterial diseases in Europe; 2012 <http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/Surveillance%20of%20IBD%20in%20Europe%202012.pdf> [accessed July 2017]."},{"key":"10.1016\/j.vaccine.2018.04.064_b0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jinf.2012.09.008","article-title":"Epidemiology of invasive meningococcal disease in Germany, 2002\u20132010, and impact of vaccination with meningococcal C conjugate vaccine","volume":"66","author":"Hellenbrand","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2018.04.064_b0035","doi-asserted-by":"crossref","DOI":"10.2807\/ese.17.21.20181-en","article-title":"W135 invasive meningococcal infections imported from Sub-Saharan Africa to France, January to April 2012","volume":"17","author":"Parent du Chatelet","year":"2012","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.04.064_b0040","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.4161\/hv.21794","article-title":"Meningococcal serogroup Y emergence in Europe: update 2011","volume":"8","author":"Broker","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.04.064_b0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4269\/ajtmh.13-0763","article-title":"Awareness of meningococcal disease among travelers from the United Kingdom to the meningitis belt in Africa","volume":"91","author":"Goodman","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.04.064_b0050","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.064_b0055","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jinf.2016.06.010","article-title":"Early evidence of expanding W ST-11 CC meningococcal incidence in Spain","volume":"73","author":"Abad","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2018.04.064_b0060","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.28.30574","article-title":"A cluster of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup W among university students, France, February to May 2017","volume":"22","author":"Bassi","year":"2017","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.04.064_b0065","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.23.30549","article-title":"Necrotising fasciitis as atypical presentation of infection with emerging Neisseria meningitidis serogroup W (MenW) clonal complex 11, the Netherlands, March 2017","volume":"22","author":"Russcher","year":"2017","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.04.064_b0070","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.45.30395","article-title":"An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015","volume":"21","author":"Lucidarme","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.04.064_b0075","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(02)08416-7","article-title":"Development of vaccines against meningococcal disease","volume":"359","author":"Jodar","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.vaccine.2018.04.064_b0080","unstructured":"European Center for Disease Prevention and Control. Vaccine Scheduler. Meningococcal disease: recommended vaccinations <https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1> [accessed in January 2017]."},{"key":"10.1016\/j.vaccine.2018.04.064_b0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1179\/2047773214Y.0000000126","article-title":"Global practices of meningococcal vaccine use and impact on invasive disease","volume":"108","author":"Ali","year":"2014","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.vaccine.2018.04.064_b0090","unstructured":"Menveo. Summary of product characteristics <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001095\/WC500090147.pdf> [accessed July 2017]."},{"key":"10.1016\/j.vaccine.2018.04.064_b0095","unstructured":"Nimenrix. Summary of product characteristics <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002226\/WC500127663.pdf> [accessed July 2017]."},{"key":"10.1016\/j.vaccine.2018.04.064_b0100","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.064_b0105","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.4161\/hv.22165","article-title":"A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2\u201310 years","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.04.064_b0110","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/INF.0000000000000866","article-title":"Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial","volume":"34","author":"Baxter","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.064_b0115","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/INF.0000000000001123","article-title":"Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in healthy children","volume":"35","author":"Klein","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.064_b0120","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","article-title":"Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine","volume":"12","author":"Vesikari","year":"2016","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2018.04.064_b0125","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/509619","article-title":"Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom","volume":"194","author":"Auckland","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.064_b0130","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.vaccine.2015.02.049","article-title":"Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.064_b0135","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1016\/j.vaccine.2012.02.046","article-title":"Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations","volume":"30","author":"Khatami","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.064_b0140","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo(R)) or Menactra(R) among healthy adolescents","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vacc"},{"key":"10.1016\/j.vaccine.2018.04.064_b0145","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0b013e318279ac38","article-title":"Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents","volume":"32","author":"Jacobson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.064_b0150","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1086\/500512","article-title":"Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine","volume":"193","author":"Vu","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.064_b0155","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.04.064_b0160","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2018.04.064_b0165","unstructured":"Public Health England. Introduction of MenACWY vaccine; 2015 <https:\/\/www.gov.uk\/government\/collections\/meningococcal-acwy-menacwy-vaccination-programme> [accessed in January 2018]."},{"key":"10.1016\/j.vaccine.2018.04.064_b0170","unstructured":"England PH. Removal of the infant dose of meningococcal serogroup C (MenC) conjugate vaccine given at three months from 1 July 2016 <https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/512311\/2016_MenC_infant_schedule_letter-FINAL__1_.pdf> [accessed in March 2018]."},{"key":"10.1016\/j.vaccine.2018.04.064_b0175","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1542\/peds.2011-2380","article-title":"D. Meningococcal conjugate vaccines policy update: booster dose recommendations","volume":"128","author":"Committee on Infectious","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.04.064_b0180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","article-title":"Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source","volume":"30","author":"Gill","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.064_b0185","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2015.07.019","article-title":"Serum bactericidal antibody assays - the role of complement in infection and immunity","volume":"33","author":"McIntosh","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.064_b0190","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2016.05.009","article-title":"Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers","volume":"34","author":"Bona","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.064_b0195","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00431-012-1924-0","article-title":"Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2\u201310-year-old children: results of an open, randomised, controlled study","volume":"172","author":"Knuf","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2018.04.064_b0200","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.04.064_b0205","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"ES. The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.vaccine.2018.04.064_b0210","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Statist Med"},{"key":"10.1016\/j.vaccine.2018.04.064_b0215","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.064_b0220","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.22166","article-title":"Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.04.064_b0225","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.vaccine.2013.07.083","article-title":"Effectiveness of meningococcal serogroup C vaccine programmes","volume":"31","author":"Borrow","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.064_b0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2334-12-35","article-title":"Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands","volume":"12","author":"Kaaijk","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.064_b0235","doi-asserted-by":"crossref","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","article-title":"Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine","volume":"5","author":"de Voer","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.04.064_b0240","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:26:19Z","timestamp":1759400779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18305619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":48,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0264410X18305619"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody persistence and booster response 68\u202fmonths after vaccination at 2\u201310\u202fyears of age with one dose of MenACWY-TT conjugate vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}